Catalyst Pharmaceuticals (CPRX) Net Margin (2018 - 2026)

Catalyst Pharmaceuticals' Net Margin history runs 9 years deep, the most recent figure standing at 42.66% for Q1 2026.

• Quarterly Net Margin rose 254.0% year-over-year to 42.66% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 38.69% (up 178.0% YoY) and the FY2025 annual result came in at 38.03%, up 470.0% from the prior year.
• Net Margin was 42.66% for Q1 2026 at Catalyst Pharmaceuticals, up from 40.85% in the prior quarter.
• Across five years, Net Margin topped out at 42.66% in Q1 2026 and bottomed at 29.96% in Q3 2023.
• A 5-year average of 31.55% and a median of 35.57% in 2025 frame the typical range for Net Margin.
• Annual changes were most pronounced in 2023 — Net Margin slumped 6970 bps — and 2024, when it surged 6406 bps.
• Catalyst Pharmaceuticals' Net Margin stood at 41.92% in 2022, then sank by 63 bps to 15.41% in 2023, then jumped by 156 bps to 39.44% in 2024, then climbed by 4 bps to 40.85% in 2025, then advanced by 4 bps to 42.66% in 2026.
• Business Quant data shows CPRX's Net Margin at 42.66% in Q1 2026, 40.85% in Q4 2025, and 35.57% in Q3 2025.